KRBP (Kiromic BioPharma) NonCurrent Deferred Liabilities : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kiromic BioPharma NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Kiromic BioPharma's non-current deferred liabilities for the quarter that ended in Sep. 2024 was $0.00 Mil.

Kiromic BioPharma NonCurrent Deferred Liabilities Historical Data

The historical data trend for Kiromic BioPharma's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiromic BioPharma NonCurrent Deferred Liabilities Chart

Kiromic BioPharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

NonCurrent Deferred Liabilities

Get a 7-Day Free Trial

Kiromic BioPharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Kiromic BioPharma NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Kiromic BioPharma's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiromic BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiromic BioPharma Inc (OTCPK:KRBP) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

7707 Fannin Street, Suite 140, Houston, TX, USA, 77054

Website

https://www.kiromic.com

Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.

Executives

Pietro Bersani	director	C/O FUEL SYSTEMS SOLUTIONS, INC., 780 THIRD AVE. 25TH FLOOR, NEW YORK NY 10017
Brian Hungerford	officer: CFO	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Pamela Misajon	director	7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Michael Nagel	director	C/O VASCULAR SOLUTIONS INC, 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Michael Catlin	director	7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Karen Reeves	director	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Francis X Tirelli	director	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Daniel Grant Clark	officer: Interim CFO	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Internati Maurizio Chiriva	director, officer: Chairman, CEO, and President	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Michael Charles Ryan	officer: Chief Technology Officer	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Ignacio Nunez	officer: See Remarks	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Jerry A. Schneider	director	ONE VISION DRIVE, NATICK MA 01760
Scott Dahlbeck	officer: Chief Medical Officer	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Americo Cicchetti	director	7707 FANNIN, SUITE 140, HOUSTON TX 77054
Gianluca Rotino	director, officer: CSIO	7707 FANNIN, SUITE 140, HOUSTON TX 77054